CoChat

Liraglutide Attenuates Preestablished Atherosclerosis in Apolipoprotein E–Deficient Mice via Regulation of Immune Cell Phenotypes and Proinflammatory Mediators

Open access
Bruen, Robyn, Curley, Seán, Kajani, Sarina, Lynch, Gina, O’Reilly, Marcella E., Dillon, Eugène T., Brennan, Eoin P., Barry, Mary, Sheehan, Stephen, McGillicuddy, Fiona C., Belton, Orina · 2019 · The Journal of Pharmacology and Experimental Therapeutics
Cited by 52

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

We have shown that the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide (Lir) inhibits development of early atherosclerosis in vivo by modulating immune cell function. We hypothesized that Lir could attenuate pre-established disease by modulating monocyte or macrophage phenotype to induce atheroprotective responses. Human atherosclerotic plaques obtained postendarterectomy and human peripheral blood macrophages were treated ex vivo with Lir. In parallel, apolipoprotein E–deficient (ApoE−/−) mice received a high-fat, high-cholesterol diet to induce atherosclerosis for 8 weeks, after which ApoE−/− mice received 300 μg/kg of Lir daily or vehicle control for a further 4 weeks to investigate the attenuation of atherosclerosis. Lir inhibited proinflammatory monocyte chemoattractant protein-1 secretion from human endarterectomy samples and monocyte chemoattractant protein-1, tumor necrosis factor-α, and interleukin (IL)-1β secretion from human macrophages after ex vivo treatment. An increase in CD206 mRNA and IL-10 secretion was also detected, which implies resolution of inflammation. Importantly, Lir significantly attenuated pre-established atherosclerosis in ApoE−/− mice in the whole aorta and aortic root. Proteomic analysis of ApoE−/− bone marrow cells showed that Lir upregulated the proinflammatory cathepsin protein family, which was abolished in differentiated macrophages. In addition, flow cytometry analysis of bone marrow cells induced a shift toward reduced proinflammatory and increased anti-inflammatory macrophages. We concluded that Lir attenuates pre-established atherosclerosis in vivo by altering proinflammatory mediators. This is the first study to describe a mechanism through which Lir attenuates atherosclerosis by increasing bone marrow proinflammatory protein expression, which is lost in differentiated bone marrow–derived macrophages. This study contributes to our understanding of the anti-inflammatory and cardioprotective role of GLP-1RAs. SIGNIFICANCE STATEMENT It is critical to understand the mechanisms through which liraglutide (Lir) mediates a cardioprotective effect as many type 2 diabetic medications increase the risk of myocardial infarction and stroke. We have identified that Lir reduces proinflammatory immune cell populations and mediators from plaque-burdened murine aortas in vivo and augments proresolving bone marrow–derived macrophages in attenuation of atherosclerotic disease, which provides further insight into the atheroprotective effect of Lir.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1124/jpet.119.258343

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Research works printed but not linked: 20

  1. Bisgaard, 2016, Liraglutide reduces both atherosclerosis and kidney inflammation in moderately uremic LDLr−/− mice, PLoS One, 11, e0168396, 10.1371/journal.pone.0168396 · DOI · Paper page
  2. Bornfeldt, 2011, Insulin resistance, hyperglycemia, and atherosclerosis, Cell Metab, 14, 575, 10.1016/j.cmet.2011.07.015 · DOI · Paper page
  3. Brennan, 2018, Lipoxins regulate the early growth response-1 network and reverse diabetic kidney disease, J Am Soc Nephrol, 29, 1437, 10.1681/ASN.2017101112 · DOI
  4. Bruen, 2017, Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis, Cardiovasc Diabetol, 16, 143, 10.1186/s12933-017-0626-3 · DOI · Paper page
  5. de Gaetano, 2015, Conjugated linoleic acid induces an atheroprotective macrophage MΦ2 phenotype and limits foam cell formation, J Inflamm (Lond), 12, 15, 10.1186/s12950-015-0060-9 · DOI
  6. de Gaetano, 2016, M1- and M2-type macrophage responses are predictive of adverse outcomes in human atherosclerosis, Front Immunol, 7, 275, 10.3389/fimmu.2016.00275 · DOI · Paper page
  7. Ding, 2015, Serum levels of monocyte chemoattractant protein-1 and all-cause and cardiovascular mortality among patients with coronary artery disease, PLoS One, 10, e0120633, 10.1371/journal.pone.0120633 · doi:10.1371/journal.pone.0120633
  8. Erbel, 2014, A human ex vivo atherosclerotic plaque model to study lesion biology, J Vis Exp, 87, 1
  9. Fadini, 2013, An unbalanced monocyte polarisation in peripheral blood and bone marrow of patients with type 2 diabetes has an impact on microangiopathy, Diabetologia, 56, 1856, 10.1007/s00125-013-2918-9 · DOI
  10. Fujisaka, 2009, Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice, Diabetes, 58, 2574, 10.2337/db08-1475 · DOI · Paper page
  11. Gaspari, 2011, A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model, Diab Vasc Dis Res, 8, 117, 10.1177/1479164111404257 · DOI · Paper page
  12. Gerhard, 1999, Homocysteine and atherosclerosis, Curr Opin Lipidol, 10, 417, 10.1097/00041433-199910000-00006 · DOI · Paper page
  13. Lusis, 2000, Atherosclerosis, Nature, 407, 233, 10.1038/35025203 · DOI · Paper page
  14. McCarthy, 2013, IL-10 mediates the immunoregulatory response in conjugated linoleic acid-induced regression of atherosclerosis, FASEB J, 27, 499, 10.1096/fj.12-215442 · DOI
  15. Nikiforov, 2017, Proinflammatory monocyte polarization in type 2 diabetes mellitus and coronary heart disease, Vessel Plus, 1, 192
  16. O’Reilly, 2016, High-density lipoprotein proteomic composition, and not efflux capacity, reflects differential modulation of reverse cholesterol transport by saturated and monounsaturated fat diets, Circulation, 133, 1838, 10.1161/CIRCULATIONAHA.115.020278 · DOI
  17. Rahman, 2017, Inflammatory Ly6Chi monocytes and their conversion to M2 macrophages drive atherosclerosis regression, J Clin Invest, 127, 2904, 10.1172/JCI75005 · DOI · Paper page
  18. Ross, 1993, The pathogenesis of atherosclerosis: a perspective for the 1990s, Nature, 362, 801, 10.1038/362801a0 · DOI · Paper page
  19. Ye, 2016, Inhibition of M1 macrophage activation in adipose tissue by berberine improves insulin resistance, Life Sci, 166, 82, 10.1016/j.lfs.2016.09.025 · DOI
  20. Zhao, 2016, The function of cathepsins B, D, and X in atherosclerosis, Am J Cardiovasc Dis, 6, 163

Cited by

See all 52

Metadata

Authors
Bruen, R., Curley, S., Kajani, S., Lynch, G., O’Reilly, M. E., Dillon, E. T., Brennan, E. P., Barry, M., Sheehan, S., McGillicuddy, F. C., & Belton, O.
Venue
The Journal of Pharmacology and Experimental Therapeutics
Publisher
Elsevier BV
Published
2019-09
Volume
370
Issue
3
Pages
447-458
ISSN
0022-3565 (ISSN-L)
OpenAlex
W2953693496
Cited by
52
References
11
FWCI
1.84
Type
journal article
Language
en
Open access
bronze
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Liraglutide Attenuates Preestablished Atherosclerosis in Apolipoprotein E–Deficient Mice via Regulation of Immune Cell Phenotypes and Proinflammatory Mediators. https://app.cochat.ai/papers/10.1124/jpet.119.258343
The paper
Bruen, R., Curley, S., Kajani, S., Lynch, G., O’Reilly, M. E., Dillon, E. T., Brennan, E. P., Barry, M., Sheehan, S., McGillicuddy, F. C., & Belton, O. (2019). Liraglutide Attenuates Preestablished Atherosclerosis in Apolipoprotein E–Deficient Mice via Regulation of Immune Cell Phenotypes and Proinflammatory Mediators. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1124/jpet.119.258343

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.